CombiGene was granted 3,3 million euro in the latest Phase 2 round in the HorizonCombiGene was granted 3,3 million euro in the latest Phase 2 round in the Horizon2020 SME Instrument programme. GAEU Consulting wrote the EU application andguided the research company through the application procedure.
The aim of the project is development and commercialization of the company’s gene therapy project focusing on difficult-to-treat epilepsy.
Mr. Jan Nilsson, CEO, CombiGene:
“GAEU has in a significant way contributed to the successful outcome of our Horizon 2020application. Both their experience of the complex application procedure and the professional hands-on support that we got throughout the entire process were very valuable. I look forward to a continued cooperation with them in the future.”
Mr. Tomasz Wasik, head of GAEU Horizon 2020 Centre of Excellence:
“Our formula is to put together a tailor-made team of experts with high commercial andacademic acumen. The application is being produced in good partnerships with our customers. We only use our own personnel. In this project Damla Khan, PhD and R&I funding specialist, took the lead and did a fantastic job".
Pictures for free publication are available in the Press Room at www.gaeu.com